Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Therapeutics

Background:

• Poor adherence to oral pharmacotherapy is a significant challenge in bipolar disorder maintenance treatment.
• This non-adherence increases the risk of relapse, rehospitalization, and adverse outcomes.
• Long-acting injectable (LAI) antipsychotics are being re-evaluated for their potential to improve treatment adherence and outcomes.

Purpose of the Study:

• To evaluate the efficacy and tolerability of long-acting injectable risperidone (RLAI) for maintenance treatment in bipolar I disorder.
• To assess RLAI's effectiveness in preventing relapse and hospitalizations compared to oral treatments or placebo.

Main Methods:

• Review of evidence including nonrandomized, open-label, randomized open-label, and randomized double-blind trials.
• Analysis of studies assessing relapse prevention, time to relapse, and clinical symptom control.
• Evaluation of tolerability and adverse event profiles, including extrapyramidal side effects and prolactin elevation.

Main Results:

• RLAI demonstrated effectiveness in preventing relapse and hospitalization in bipolar maintenance treatment.
• Double-blind studies showed RLAI reduced relapse rates and improved symptom control compared to oral medication or placebo.
• RLAI was more effective in preventing manic/mixed episodes than depressive episodes.
• Common side effects included extrapyramidal effects, sedation, weight gain, and prolactin elevation.

Conclusions:

• Long-acting injectable risperidone (RLAI) is an effective option for bipolar disorder maintenance therapy, particularly for preventing manic episodes.
• While generally well-tolerated, potential side effects require monitoring during long-term treatment.
• Limitations in study designs, such as responder-enriched populations, may affect the generalizability of findings to routine clinical practice.